Hottest Stories: Zuoan Fashion Limited (NYSE:ZA), Farmland Partners (NYSEMKT:FPI), JD.com (NASDAQ:JD), the Rubicon Project (NYSE:RUBI), Trevena (NASDAQ:TRVN)

Zuoan Fashion Limited (NYSE:ZA) shares remains unchanged in last trading session and ended the day at $1.40. ZA Gross Margin is 30.10% and its has a return on assets of 0.00%. Zuoan Fashion Limited (NYSE:ZA) quarterly performance is -58.58%.

Zuoan Fashion Ltd. (Zuoan) is a China-based casual menswear company. The Company’s products are designed in-house and sold under its Zuoan brand. The Company offers a range of products, including men’s casual apparel, footwear and lifestyle accessories, primarily targeting urban males between the ages of 20 and 40.

Farmland Partners Inc. (NYSEMKT:FPI) ended the last trading day at $10.49. Company weekly volatility is calculated as 1.47% and price to cash ratio as 5.86. Farmland Partners Inc. (NYSEMKT:FPI) showed a weekly performance of 1.04%.

Farmland Partners Inc. (FPI) (the “Company”) announced that its Board of Directors approved a quarterly cash dividend of $0.1275 per share to be paid on October 15, 2015 to stockholders of record at the close of business on October 1, 2015. The annualized dividend of $0.51 per share represents a 4.73% yield based on the closing price of the Company’s common stock on August 11, 2015.

Farmland Partners Inc. (NYSEMKT:FPI) announced that its Board of Directors approved a quarterly cash dividend of $0.1275 per share to be paid on October 15, 2015 to stockholders of record at the close of business on October 1, 2015. The annualized dividend of $0.51 per share represents a 4.73% yield based on the closing price of the Company’s common stock on August 11, 2015.

On 01 September, JD.com, Inc. (NASDAQ:JD) shares decreased -3.86% and was closed at $24.88. JD.com, Inc. (NASDAQ:JD) year to date (YTD) performance is 7.52%.

JD.com, Inc. is China’s leading online direct sales company and the country’s largest Internet company by revenue. The Company strives to offer consumers the best online shopping experience. Through its content-rich and user-friendly website jd.com and mobile applications, JD.com offers a wide selection of authentic products at competitive prices and delivers products in a speedy and reliable manner.

On 28 August, JD.com, Inc. (NASDAQ:JD), announced partnerships with Australian brands Blackmores, a leading Australian natural health company, and Sanger Australia, the Australian meat sales and marketing business of the Bindaree Beef Group. Both brands will be available through JD.com’s direct sales channel and will use the company’s industry-leading same-day delivery capabilities. Sanger Australia will also leverage JD.com’s cold chain logistics network to ensure that its meat products are delivered fresh to Chinese customers from Australia.

the Rubicon Project, Inc. (NYSE:RUBI) shares moved up 0.07% in last trading session and ended the day at $14.41. RUBI Gross Margin is 80.50% and its has a return on assets of -6.30%. the Rubicon Project, Inc. (NYSE:RUBI) quarterly performance is -15.53%.

Rubicon Project (RUBI) has engineered the Advertising Automation Cloud, one of the largest real-time cloud and Big Data computing systems. The Company’s mission is to automate the buying and selling of advertising by offering innovative products to connect buyers and sellers globally.

Rubicon Project (NYSE:RUBI), disclosed for the first time the success of its rapidly growing direct order automation business. Managed Revenue from the overall Orders business (which comprises Guaranteed Orders + Non-Guaranteed Orders) grew more than 150% year-over-year in the second quarter of 2015. Rubicon Project’s burgeoning Mobile Orders business also experienced significant growth during that time period increasing by nearly 200%.

Trevena, Inc. (NASDAQ:TRVN) caters to the Healthcare space. Its weekly performance is 62.32%. On the last day of trading company shares ended up $9.09. Trevena, Inc. (NASDAQ:TRVN) distance from 50-day simple moving average (SMA50) is 44.79%.

Trevena Inc. (Trevena) is a clinical-stage biopharmaceutical company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: TRV130, a small molecule G protein biased ligand at the mu-opioid receptor to treat patients experiencing moderate to severe acute pain where IV administration is preferred; TRV734, a small molecule G protein biased ligand at the mu-opioid receptor to treat moderate to severe acute and chronic pain, and TRV027, a peptide b-arrestin biased ligand that targets the angiotensin II type 1 receptor (AT1R), inhibiting G protein signaling and activating b-arrestin signaling.

Trevena, Inc. (NASDAQ:TRVN), announced positive data from its randomized, double-blind, placebo- and active-controlled Phase 2b trial of TRV130 in moderate to severe acute postoperative pain after abdominoplasty surgery. The study achieved its primary endpoint of statistically greater pain reduction than placebo over 24 hours.